Piper Sandler Increases Cue Biopharma (NASDAQ:CUE) Price Target to $8.00

Cue Biopharma (NASDAQ:CUE) had its price objective increased by stock analysts at Piper Sandler from $7.00 to $8.00 in a report released on Monday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price target points to a potential upside of 213.73% from the stock’s current price.

Cue Biopharma Stock Performance

CUE opened at $2.55 on Monday. The firm has a market cap of $114.65 million, a price-to-earnings ratio of -2.02 and a beta of 1.97. Cue Biopharma has a 52 week low of $1.70 and a 52 week high of $5.12. The business’s 50 day moving average is $2.27 and its two-hundred day moving average is $3.31. The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.13.

Cue Biopharma (NASDAQ:CUE) last released its earnings results on Tuesday, August 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.01. The business had revenue of $1.38 million for the quarter, compared to analyst estimates of $1.21 million. Cue Biopharma had a negative return on equity of 95.36% and a negative net margin of 2,899.44%. On average, research analysts predict that Cue Biopharma will post -1.22 EPS for the current year.

Institutional Trading of Cue Biopharma

Institutional investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SNC boosted its position in Cue Biopharma by 9,270.1% during the second quarter. BNP Paribas Arbitrage SNC now owns 9,089 shares of the company’s stock worth $33,000 after purchasing an additional 8,992 shares in the last quarter. Citigroup Inc. purchased a new stake in Cue Biopharma during the second quarter worth $38,000. California State Teachers Retirement System purchased a new stake in Cue Biopharma during the second quarter worth $42,000. Mirabella Financial Services LLP purchased a new stake in shares of Cue Biopharma in the first quarter valued at $58,000. Finally, Barclays PLC lifted its position in shares of Cue Biopharma by 114.7% in the second quarter. Barclays PLC now owns 12,946 shares of the company’s stock valued at $48,000 after acquiring an additional 6,917 shares in the last quarter. 30.83% of the stock is currently owned by hedge funds and other institutional investors.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.